Impact of the COVID-19 pandemic on early-stage breast cancer post-lumpectomy breast radiation therapy completion.
Abstract
e12682 Background: Whole-breast radiation therapy (RT) following lumpectomy has become a standard of care for early-stage breast cancer (ESBC) treatment. Previous research has demonstrated superior compliance with hypofractionation (HFRT) versus standard fractionation (SFRT). However, the impact of the COVID-19 pandemic on RT completion rates in ESBC has not been well-characterized. Methods: Using the National Cancer Database, patients with ESBC who underwent post-lumpectomy RT from 2018 to 2022 were identified. SFRT was defined as 1.8-2.0 Gray (Gy) per fraction and HFRT as 2.66-2.70 Gy per fraction. RT completion was defined as receipt of ≥46 Gy for SFRT and ≥40 Gy for HFRT. Pre-COVID (2018-2019) and post-COVID (2021-2022) RT completion rates were compared using chi-square tests. Results: Among 25,658 patients, (pre-COVID n=13,381; post-COVID n=12,277), HFRT use increased from 82.9% to 93.6% (p< 0.0001), while SFRT declined (17.1% to 6.4%, p< 0.001). Overall RT completion improved from 94.8% to 96.4% (p< 0.0001). HFRT completion rates remained stable and were higher than SFRT (pre-COVID: 97.2% vs. 83.1%, post-COVID: 97.5% vs. 80.5%, p< 0.0001). HFRT adoption rose across all racial and income groups (p< 0.0001), with completion exceeding 96% across all subgroups. Racial differences in HFRT use decreased from 16.3 to 7.6 percentage points, while income-related differences decreased from 7.4 to 4.4 percentage points. Conclusions: Post-COVID, HFRT adoption after lumpectomy increased while SFRT use decreased by 62.6% of pre-COVID levels. These shifts were accompanied by completion rates exceeding 96% across all groups. A 53.3% and 40.5% relative reduction in racial- and income-related disparities in use were observed, suggesting more equitable treatment delivery. HFRT adoption pre- and post-COVID by race. SFRT HFRT Race Count % Count % p White 2018-2019 (Pre-COVID) 1865 16.32 9565 83.68 <.0001 2021-2022 (Post-COVID) 619 6.02 9669 93.98 African American 2018-2019 (Pre-COVID) 330 26.59 911 73.41 <.0001 2021-2022 (Post-COVID) 133 11.45 1029 88.55 Asian or Pacific Islander 2018-2019 (Pre-COVID) 45 10.34 390 89.66 <.0001 2021-2022 (Post-COVID) 19 3.81 480 96.19 Other or Unknown 2018-2019 (Pre-COVID) 52 18.91 223 81.09 <.0001 2021-2022 (Post-COVID) 18 5.49 310 94.51
Article Details
Journal Info
Journal of Clinical Oncology
Lippincott Williams & Wilkins
Authors (5)
Alexandra Stump
Department of Psychological and Brain Sciences, University of California
Marie Gordon
3The Univ. of OK Health Sciences Ctr., Oklahoma, United States
Evan Becker
University of Oklahoma Hudson College of Public Health, Oklahoma City, OK
Kai Ding
Shearwood McClelland
Stephenson Cancer Center, Departments of Radiation Oncology and Neurological Surgery, The University of Oklahoma College of Medicine, Oklahoma City, OK